• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Infect . Effectiveness of BNT162b2 vaccine against the B.1.1.7 variant of SARS-CoV-2 among healthcare workers in Brescia, Italy

tetano

Editor, Senior Moderator
J Infect


. 2021 May 6;S0163-4453(21)00225-5.
doi: 10.1016/j.jinf.2021.04.038. Online ahead of print.
Effectiveness of BNT162b2 vaccine against the B.1.1.7 variant of SARS-CoV-2 among healthcare workers in Brescia, Italy


E Sansone[SUP] 1 [/SUP], M Tiraboschi[SUP] 1 [/SUP], E Sala[SUP] 2 [/SUP], E Albini[SUP] 2 [/SUP], M Lombardo[SUP] 3 [/SUP], F Castelli[SUP] 4 [/SUP], G De Palma[SUP] 5 [/SUP]



Affiliations

Abstract

Objectives: The aim of the study was to evaluate the effectiveness of BNT162b2 vaccine (Pfizer?) among healthcare workers (HCWs) while a recrudescence of pandemics was hitting the Brescia county, with a high rate of the B.1.1.7 variant.
Methods: The study was performed in the context of the mandatory health surveillance at the workplaces, in the period between 25th January 2021 and 26th March 2021, when 6904 HCWs (78% of workforce) gained full protection. HCWs were classified by having received the full vaccine schedule or not. The SARS-CoV-2 infection was diagnosed by conventional RT-PCR on rhino-pharyngeal swabs, followed by gene sequencing in positive vaccinated HCWs.
Results: We observed 84 SARS-CoV-2 infections among HCWs, most among unvaccinated HCWs. Gene sequencing was successful in 5 cases only, 4 B.1.1.7 and 1 B1.525 variants. In the same period, Lombardy registered 192.829 confirmed COVID-19 cases, 40.029 of which in Brescia county. The incidence rate of the B.1.1.7 variant rose from 70% to 97%.
Conclusions: Results confirm the protective effects of BNT162b2. The vaccine campaign was effective not only in reducing the appearance of symptoms but also in decreasing the incidence of infections among vaccinated HCWs. We observed a reduced infection rate also among the residual unvaccinated HCWs.

Keywords: COVID-19; Coronavirus; herd immunity; vaccine.
 
Back
Top Bottom